title: Efficacy of brimonidine 0.2 per cent as adjunctive therapy to beta-blockers: a comparative study between POAG and CACG in Asian eyes.
abstract: OBJECTIVE
  To compare the efficacy and safety profile of brimonidine as adjunctive therapy to beta-blockers between primary open angle glaucoma (POAG) and chronic angle closure glaucoma (CACG) in Asian eyes.
  
  
  METHODS
  Three-months, open-label, prospective study.
  
  
  METHODS
  Twenty-three patients (35 eyes) with POAG and 25 patients (39 eyes) with CACG were enrolled in the study.
  
  
  METHODS
  Patients with POAG or CACG post iridectomy whose IOP was inadequately controlled with topical beta-blocker monotherapy were included. Then, brimonidine 0.2 per cent was added twice daily in both groups. Study visit occurred at weeks 2, 4, 8, and 12. Complete ophthalmic examinations were performed in all visits.
  
  
  METHODS
  Efficacy was determined by reduction in IOP from baseline and tolerability was assessed by reports of adverse events.
  
  
  RESULTS
  After 3 months of brimonidine adjunctive treatment, the mean (+/- SEM) IOP reduction were 4.37+/-0.34 mmHg (19.4%) in POAG and 4.54+/-0.37 mmHg (20.1%) in CACG (p= 0.741). No serious ocular or systemic adverse event was reported.
  
  
  CONCLUSIONS
  Brimonidine was well tolerated, efficacious and provided additive IOP reduction in POAG and CACG.
authors.affiliation: Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
authors.forename: Ngamkae
authors.initials: N
authors.lastname: Ruangvaravate
authors.forename: Naris
authors.initials: N
authors.lastname: Kitnarong
authors.forename: Ankana
authors.initials: A
authors.lastname: Metheetrairut
authors.forename: Wimolrat
authors.initials: W
authors.lastname: Danwiriyakul
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000068438:Brimonidine Tartrate; D004359:Drug Therapy, Combination; D005260:Female; D015812:Glaucoma, Angle-Closure / Q000188:drug therapy*; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011810:Quinoxalines / Q000627:therapeutic use*; D013785:Thailand; D016896:Treatment Outcome
chemical_list: D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D011810:Quinoxalines; D000068438:Brimonidine Tartrate